Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 29, 2021 07:00 ET | Source: Agios Pharmaceuticals, Inc.

Agios Reports Business Highlights and First Quarter 2021 Financial Results

– Data from ACTIVATE and ACTIVATE-T Phase 3 Studies of Mitapivat in Pyruvate Kinase (PK) Deficiency and Phase 2 Study of Mitapivat in Thalassemia Accepted for Presentation at EHA 2021 Virtual Congress...
April 15, 2021 07:00 ET | Source: Agios Pharmaceuticals, Inc.

Agios to Webcast Conference Call of First Quarter 2021 Financial Results on April 29, 2021

CAMBRIDGE, Mass., April 15, 2021 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat genetically defined diseases, today announced...
April 01, 2021 07:00 ET | Source: Agios Pharmaceuticals, Inc.

Agios Announces Closing of Oncology Business Sale to Servier

Agios Receives $1.8 Billion in Upfront Cash to Focus on Accelerating and Expanding its Genetically Defined Disease Portfolio Agios Enters Into Agreement to Repurchase Approximately 10% of Its...
March 25, 2021 16:01 ET | Source: Agios Pharmaceuticals, Inc.

Agios Shareholders Approve Sale of Oncology Business to Servier

CAMBRIDGE, Mass., March 25, 2021 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat genetically defined diseases, today announced...
March 18, 2021 07:00 ET | Source: Agios Pharmaceuticals, Inc.

Agios Sponsors Program Promoting Health Literacy for Patients with Sickle Cell Disease

CAMBRIDGE, Mass., March 18, 2021 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat cancer and genetically defined diseases, today...
March 01, 2021 07:00 ET | Source: Agios Pharmaceuticals, Inc.

Agios Submits Supplemental New Drug Application to FDA for TIBSOVO® (ivosidenib tablets) for Patients with Previously Treated IDH1-Mutant Cholangiocarcinoma

CAMBRIDGE, Mass., March 01, 2021 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat cancer and genetically defined diseases, today...
February 26, 2021 07:00 ET | Source: Agios Pharmaceuticals, Inc.

Agios Recognizes 14th Annual Rare Disease Day and Raises Awareness of Unmet Needs in Rare Hemolytic Anemias

– In Partnership with the Sickle Cell Community Consortium, Agios Works to Address Educational Resource Gaps Caused by COVID-19 for Students with Sickle Cell Disease – – Company to Host Facebook Live...
February 25, 2021 07:00 ET | Source: Agios Pharmaceuticals, Inc.

Agios Reports Fourth Quarter and Full Year 2020 Financial Results

– Strong Commercial Execution for Second Full Year of TIBSOVO® with Fourth Quarter Net Revenue of $39.1M and $121.1M for Full Year 2020 – – Sale of Oncology Portfolio Expected to Close Around...
February 23, 2021 07:00 ET | Source: Agios Pharmaceuticals, Inc.

Agios to Present at March Investor Conferences

CAMBRIDGE, Mass., Feb. 23, 2021 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and genetically defined diseases, today...
February 11, 2021 07:00 ET | Source: Agios Pharmaceuticals, Inc.

Agios to Webcast Conference Call of Fourth Quarter and Year End 2020 Financial Results on February 25, 2021

CAMBRIDGE, Mass., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat cancer and genetically defined diseases, today...